PCN66 COST EVALUATION OF THE CROSS PROTECTION DIFFERENCE BETWEEN THE BIVALENT AND QUADRIVALENT HPV VACCINE AGAINST CERVICAL CANCER WITHIN EUROPEAN COUNTRIES
Oct 1, 2009, 00:00 AM
10.1016/S1098-3015(10)74317-5
https://www.valueinhealthjournal.com/article/S1098-3015(10)74317-5/fulltext
Section Title :
Section Order :
245
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)74317-5&doi=10.1016/S1098-3015(10)74317-5